Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Lung cancer remains a leading cause of cancer-related mortality worldwide.
• Developing effective combination therapies is crucial for improving patient outcomes.
• Noscapine and Cisplatin are established agents with known anticancer properties.

Purpose of the Study:

• To evaluate the in vitro and in vivo efficacy of combining Noscapine (Nos) and Cisplatin (Cis) for lung cancer treatment.
• To investigate the underlying molecular mechanisms of the Nos+Cis combination therapy.
• To assess the synergistic potential and impact on cancer cell apoptosis and signaling pathways.

Main Methods:

• In vitro studies using A549 and H460 non-small cell lung cancer (NSCLC) cell lines.
• In vivo efficacy assessment in a murine xenograft lung cancer model.
• Analysis of apoptosis markers, cell cycle regulators, and key signaling proteins (e.g., p53, Bcl-2, Akt, caspases).

Main Results:

• Combination index values (< 0.6) indicated synergistic effects of Nos+Cis.
• Nos+Cis significantly increased NSCLC cell apoptosis and tumor volume reduction (78.1%) compared to single agents.
• The combination modulated key proteins involved in apoptosis (e.g., increased Bax, cleaved caspase 3; decreased Bcl-2) and cell signaling (e.g., decreased pAkt, cyclin D1).

Conclusions:

• Noscapine enhances the anticancer activity of Cisplatin in an additive to synergistic manner.
• The combination therapy activates multiple pro-apoptotic signaling pathways.
• These findings support the potential clinical benefit of using Noscapine and Cisplatin in combination for lung cancer treatment.